
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic is in a strong position with their lead asset vidofludimus calcium, which has shown positive results in both their Phase 2 EMPhASIS trial and with their recently announced Phase 3 ENSURE program in relapsing-remitting multiple sclerosis. Despite a capital-intensive nature of their late-stage program, their recent financing of $187M and continued investment in R&D should support an NDA filing in 2027, making it a potential favorable investment opportunity.
Bears say
Immunic is a clinical-stage biopharmaceutical company that is developing a pipeline of selective oral immunology therapies for chronic inflammatory and autoimmune diseases, but there are several risk factors that could potentially hinder their success in the market, such as clinical and regulatory challenges, financial risks, and competition in the market. Additionally, the financing deal with pre-funded warrants and potential dilution could impact their financial stability. However, their potential for targeting disease modification and their plans for upcoming Phase 3 trials could position them well for future success.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares